Uncovering the Clinical Research Propelling ILD Drug Development Forwards in 2022 & Beyond
8:30 am Registration & Networking
8:55 am Chair’s Opening Remarks
9:00 am Strategically Leveraging ILD Clinical Trials to Further Our Understanding of The Progressive Pulmonary Fibrosis Phenotype & Identify Novel Outcomes in Clinical Trials
Synopsis
• Looking at previous clinical studies to understand primary, secondary
and exploratory outcomes and how these may help to better
characterize the progressive phenotype
• Looking at response rates of differing ILD diagnosis’ within previous
clinical trials in patients with the progressive phenotype
• Investigating previous exploratory/new composite outcomes and
understanding how to use them in new clinical trails given the existing
standard of care
9:30 am Looking Beyond IPF: Utilizing Lessons Learned from IPF Clinical Trials to Inform & Optimize Your ILD Trial Design & Execution
Synopsis
- Discussing the applicability of extrapolating data from IPF to other
disease - Defining which ILD states are most believable to lump together with IPF
- Evaluating criteria used to lump and split, spotlight on CT imaging,
clinical characteristics, lung limited disease and more
10:00 am Uncovering Trial Design Considerations in Sarcoid
Synopsis
- Investigating the complexities of Sarcoid trial design
- Examining CMK-389 in sarcoid
- Gaining a high level overview of clinical trial design and execution
10:30 am Speed Networking
11:00 am Morning Break & Networking
Uncovering Emerging ILD Therapeutic Approaches
11:30 am Developing Therapies for Rare Lung Diseases: ILD 101
Synopsis
• Discovering VP01 (C21) for interstitial lung disease
• Outlining our therapeutic approach for interstitial lung disease – how we
strategized our ILD drug development
• Exploring challenges associated with ILD drug development and
learning how to overcome them
12:00 pm Lunch Break & Networking
1:00 pm Single vs Multiple Benefit Drugs for ILD
Synopsis
• Is it better to have a single target with multiple benefits?
• Investigating GSNOR inhibition
• Exploring single targets with no known safety issues
1:30 pm Update on Inhaled Drug Delivery: The Application of Anticalins in the Treatment of Lung Fibrosis
Synopsis
- Highlighting the benefits of local intervention via inhalation versus
systemic administration - Inhaled Anticalin antagonists for respiratory disease
- Reviewing the development of PRS-220, a potential best-in-class,
inhaled CTGF inhibitor for the treatment of IPF
Analyzing & Scrutinizing ILD Mechanisms
2:00 pm Evolution of Multicellular Hubs in the Tumor Microenvironment & their Relevance for ILD Drug Development
Synopsis
- Investigating fibroblasts as drivers of fibrotic indications for lung diseases
- Exploring tools/pharmacologic agents to target fibrotic pathways/
inflammatory pathways - Understanding the similarities and differences between cellular interactions
and molecular pathways in cancer and ILDs
2:30 pm The Role of Macrophage Metabolic Reprogramming During Pulmonary Fibrosis
Synopsis
• Macrophages play a key role in the pathogenesis of IPF, but the role of
macrophage metabolism is not well understood.
• We have found that macrophages in IPF are metabolically reprogrammed with
alterations in iron (Allden et al, AJRCCM 2019), glycolysis (McErlean et al, AJRCCM
20201) and TCA cycle (Ogger et al, Science immunology 2020) pathways
• Macrophage metabolism therefore represents an exciting therapeutic target in IPF
3:00 pm Afternoon Break & Networking
Strategizing New Target Identification for Novel Therapies 101
4:00 pm Selective Inhibition of ROCK2: Promising Approach to Target Fibrosis
Synopsis
• Understand the rationale for ROCK2 in lung fibrosis
• Assess the development of RXC007, a highly selective ROCK2 inhibitor
• Review preclinical studies in rodents and in Human Precision Cut Lung Slices
(PCLS)
4:30 pm Revealing What Steps You Must Take to Successfully Identify & Validate Novel ILD Therapeutic Targets which Target Lung Epithelial injury
Synopsis
- Examine interactions between injury repair cascade and fibrosis in IPF/ILD
- Evaluate druggability of pathways which target lung epithelial injury, repair
and regeneration - How to kickstart your ILD drug discovery program